Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development and translational research gained in leading industry and academic institutions. In his role as Chief Medical Officer, he will be responsible for clinical development activities as well as regulatory affairs. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares after opening at $26.58 moved to $27.22 on last trade day and at the end of the day closed at $25.21. Company price to sales ratio in past twelve months was calculated as 71.07 and price to cash ratio as 8.19. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) showed a negative weekly performance of -21.71%.
Liquidity Services, Inc. (NASDAQ:LQDT) Wednesday announced it has been determined the apparent high bidder for a contract with the U.S. Defense Logistics Agency (DLA) to purchase, manage and sell non-rolling stock surplus assets of the U.S. Department of Defense (DoD) (Surplus Contract). Liquidity Services, Inc.’s high bid was equal to 4.35% of the DoD’s original acquisition value (OAV). The Surplus Contract has a base term of two years with four one-year renewal options. Liquidity Services, Inc. (NASDAQ:LQDT) shares fell -6.67% in last trading session and ended the day on $20.86. LQDT return on equity ratio is recorded as 13.60% and its return on assets is 10.10%. Liquidity Services, Inc. (NASDAQ:LQDT) yearly performance is -28.88%.
Wedbush initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $10.00 price target on the stock. Wedbush’s price objective suggests a potential downside of 32.02% from the company’s current price. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved down -2.50% in last trading session and was closed at $11.30, while trading in range of $10.90-$11-80. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date performance is -18.18%.
Clifton Savings Bancorp (NASDAQ:CSBK) CEO Paul M. Aguggia purchased 65,000 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were purchased at an average price of $10.00 per share, with a total value of $650,000.00. Following the transaction, the chief executive officer now directly owns 20,000 shares in the company, valued at approximately $200,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Clifton Savings Bancorp, Inc. (NASDAQ:CSBK) weekly performance is -3.65%. On last trading day company shares ended up $11.61. Clifton Savings Bancorp, Inc. (NASDAQ:CSBK) distance from 50-day simple moving average is -8.99%. Analysts mean target price for the company is $14.00.